Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.
B Venugopal(Beatson West of Scotland Cancer Centre), Toni K. Choueiri(Dana-Farber Cancer Institute), J. Haanen(Dutch Cancer Society), Karin Tyroller(Ono Pharmaceutical (United States)), Y. Tomita(Niigata University), Manuela Schmidinger(Medical University of Vienna), Laurence Albigès(Université Paris-Saclay), R Motzer(Memorial Sloan Kettering Cancer Center), J L Lee(Asan Medical Center), Daniel Yick Chin Heng(University of Calgary), Hirotsugu Uemura(Kindai University), Konstantin Penkov, Hideaki Miyake(Kobe University), Mototsugu Oya(Keio University), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Christian K. Kollmannsberger, Jason Hoffman(Ono Pharmaceutical (United States)), James M. G. Larkin(Institute of Cancer Research), Howard Gurney(Radboud University Nijmegen)
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k